Loading…

Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract

We investigated the immunoreactivity for bcl-2 oncoprotein in 154 cases of transitional cell carcinoma of the upper urinary tract (TCC-UUT) and its relation with the immunoreactivity for p53 oncoprotein and proliferating cell nuclear antigen (PCNA) immunoreactivity. Immunohistochemically, bcl-2 onco...

Full description

Saved in:
Bibliographic Details
Published in:Virchows Archiv : an international journal of pathology 1998-05, Vol.432 (5), p.445-450
Main Authors: NAKANISHI, K, TOMINAGA, S, KAWAI, T, TORIKATA, C, AURUES, T, IKEDA, T
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c383t-d44e2e8a9cb8b07a2d7144b0b79c4b3a6857ede4eedc2fae2676ef02709aa4e83
cites
container_end_page 450
container_issue 5
container_start_page 445
container_title Virchows Archiv : an international journal of pathology
container_volume 432
creator NAKANISHI, K
TOMINAGA, S
KAWAI, T
TORIKATA, C
AURUES, T
IKEDA, T
description We investigated the immunoreactivity for bcl-2 oncoprotein in 154 cases of transitional cell carcinoma of the upper urinary tract (TCC-UUT) and its relation with the immunoreactivity for p53 oncoprotein and proliferating cell nuclear antigen (PCNA) immunoreactivity. Immunohistochemically, bcl-2 oncoprotein was recognized as positive in 29.2% of the samples. The immunoreactivity for bcl-2 oncoprotein was significantly (P < 0.05) correlated only with stage, though there was a borderline correlation (P = 0.050) with PCNA immunoreactivity. Furthermore, in invasive TCC the immunoreactivity for bcl-2 oncoprotein was associated with PCNA immunoreactivity (P < 0.041). The 5-year disease-free and overall survival rates were 55.7% and 71.5%, respectively. A univariate analysis of survival revealed that stage, grade, pattern of growth, immunoreactivity for p53 oncoprotein, and PCNA immunoreactivity each had a significant effect on disease-free and overall survival rates, whereas the immunoreactivity for bcl-2 oncoprotein had no significant effect on either rate. In the final models of the multivariate analysis, stage was found to be the only prognostic factor for disease-free survival and for overall survival. Detection of immunoreactivity for bcl-2 oncoprotein appears to be of no real value in deciding the prognosis of TCC-UUT.
doi_str_mv 10.1007/s004280050189
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79961187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79961187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-d44e2e8a9cb8b07a2d7144b0b79c4b3a6857ede4eedc2fae2676ef02709aa4e83</originalsourceid><addsrcrecordid>eNpVkElLxEAQhRtRxnH06FHIQbxFq5f0chQZFxjwogdPodOpYCSb3Qnov7fDhAGhqDq87xWPR8glhVsKoO4CgGAaIAOqzRFZU8FZyjioY7IGI7JUcqpOyVkIXwCMaipXZGWkyIQQa_Kx_Rk8hlD3XdJXSeGalCV95_rB9yPWXRJn9LYL9RgR2yQOm7isd3XXt3b2jJ-YTMOAPpl83Vn_OxvceE5OKtsEvFjuhrw_bt8entPd69PLw_0udVzzMS2FQIbaGlfoApRlpaJCFFAo40TBrdSZwhIFYulYZZFJJbECpsBYK1DzDbnZ_42JvycMY97WYU5pO-ynkCtjJKVaRTDdg873IXis8sHXbcybU8jnKvN_VUb-ank8FS2WB3rpLurXi26Ds00VW3J1OGCMCSM153_-u3xN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79961187</pqid></control><display><type>article</type><title>Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>NAKANISHI, K ; TOMINAGA, S ; KAWAI, T ; TORIKATA, C ; AURUES, T ; IKEDA, T</creator><creatorcontrib>NAKANISHI, K ; TOMINAGA, S ; KAWAI, T ; TORIKATA, C ; AURUES, T ; IKEDA, T</creatorcontrib><description>We investigated the immunoreactivity for bcl-2 oncoprotein in 154 cases of transitional cell carcinoma of the upper urinary tract (TCC-UUT) and its relation with the immunoreactivity for p53 oncoprotein and proliferating cell nuclear antigen (PCNA) immunoreactivity. Immunohistochemically, bcl-2 oncoprotein was recognized as positive in 29.2% of the samples. The immunoreactivity for bcl-2 oncoprotein was significantly (P &lt; 0.05) correlated only with stage, though there was a borderline correlation (P = 0.050) with PCNA immunoreactivity. Furthermore, in invasive TCC the immunoreactivity for bcl-2 oncoprotein was associated with PCNA immunoreactivity (P &lt; 0.041). The 5-year disease-free and overall survival rates were 55.7% and 71.5%, respectively. A univariate analysis of survival revealed that stage, grade, pattern of growth, immunoreactivity for p53 oncoprotein, and PCNA immunoreactivity each had a significant effect on disease-free and overall survival rates, whereas the immunoreactivity for bcl-2 oncoprotein had no significant effect on either rate. In the final models of the multivariate analysis, stage was found to be the only prognostic factor for disease-free survival and for overall survival. Detection of immunoreactivity for bcl-2 oncoprotein appears to be of no real value in deciding the prognosis of TCC-UUT.</description><identifier>ISSN: 0945-6317</identifier><identifier>EISSN: 1432-2307</identifier><identifier>DOI: 10.1007/s004280050189</identifier><identifier>PMID: 9645444</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Transitional Cell - metabolism ; Carcinoma, Transitional Cell - pathology ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; Kidney Neoplasms - metabolism ; Kidney Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Proliferating Cell Nuclear Antigen - metabolism ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; Survival Rate ; Tumor Suppressor Protein p53 - metabolism ; Tumors of the urinary system ; Ureteral Neoplasms - metabolism ; Ureteral Neoplasms - pathology ; Urinary tract. Prostate gland</subject><ispartof>Virchows Archiv : an international journal of pathology, 1998-05, Vol.432 (5), p.445-450</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-d44e2e8a9cb8b07a2d7144b0b79c4b3a6857ede4eedc2fae2676ef02709aa4e83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2249683$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9645444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NAKANISHI, K</creatorcontrib><creatorcontrib>TOMINAGA, S</creatorcontrib><creatorcontrib>KAWAI, T</creatorcontrib><creatorcontrib>TORIKATA, C</creatorcontrib><creatorcontrib>AURUES, T</creatorcontrib><creatorcontrib>IKEDA, T</creatorcontrib><title>Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract</title><title>Virchows Archiv : an international journal of pathology</title><addtitle>Virchows Arch</addtitle><description>We investigated the immunoreactivity for bcl-2 oncoprotein in 154 cases of transitional cell carcinoma of the upper urinary tract (TCC-UUT) and its relation with the immunoreactivity for p53 oncoprotein and proliferating cell nuclear antigen (PCNA) immunoreactivity. Immunohistochemically, bcl-2 oncoprotein was recognized as positive in 29.2% of the samples. The immunoreactivity for bcl-2 oncoprotein was significantly (P &lt; 0.05) correlated only with stage, though there was a borderline correlation (P = 0.050) with PCNA immunoreactivity. Furthermore, in invasive TCC the immunoreactivity for bcl-2 oncoprotein was associated with PCNA immunoreactivity (P &lt; 0.041). The 5-year disease-free and overall survival rates were 55.7% and 71.5%, respectively. A univariate analysis of survival revealed that stage, grade, pattern of growth, immunoreactivity for p53 oncoprotein, and PCNA immunoreactivity each had a significant effect on disease-free and overall survival rates, whereas the immunoreactivity for bcl-2 oncoprotein had no significant effect on either rate. In the final models of the multivariate analysis, stage was found to be the only prognostic factor for disease-free survival and for overall survival. Detection of immunoreactivity for bcl-2 oncoprotein appears to be of no real value in deciding the prognosis of TCC-UUT.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kidney Neoplasms - metabolism</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Proliferating Cell Nuclear Antigen - metabolism</subject><subject>Proto-Oncogene Proteins c-bcl-2 - metabolism</subject><subject>Survival Rate</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Tumors of the urinary system</subject><subject>Ureteral Neoplasms - metabolism</subject><subject>Ureteral Neoplasms - pathology</subject><subject>Urinary tract. Prostate gland</subject><issn>0945-6317</issn><issn>1432-2307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNpVkElLxEAQhRtRxnH06FHIQbxFq5f0chQZFxjwogdPodOpYCSb3Qnov7fDhAGhqDq87xWPR8glhVsKoO4CgGAaIAOqzRFZU8FZyjioY7IGI7JUcqpOyVkIXwCMaipXZGWkyIQQa_Kx_Rk8hlD3XdJXSeGalCV95_rB9yPWXRJn9LYL9RgR2yQOm7isd3XXt3b2jJ-YTMOAPpl83Vn_OxvceE5OKtsEvFjuhrw_bt8entPd69PLw_0udVzzMS2FQIbaGlfoApRlpaJCFFAo40TBrdSZwhIFYulYZZFJJbECpsBYK1DzDbnZ_42JvycMY97WYU5pO-ynkCtjJKVaRTDdg873IXis8sHXbcybU8jnKvN_VUb-ank8FS2WB3rpLurXi26Ds00VW3J1OGCMCSM153_-u3xN</recordid><startdate>19980501</startdate><enddate>19980501</enddate><creator>NAKANISHI, K</creator><creator>TOMINAGA, S</creator><creator>KAWAI, T</creator><creator>TORIKATA, C</creator><creator>AURUES, T</creator><creator>IKEDA, T</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980501</creationdate><title>Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract</title><author>NAKANISHI, K ; TOMINAGA, S ; KAWAI, T ; TORIKATA, C ; AURUES, T ; IKEDA, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-d44e2e8a9cb8b07a2d7144b0b79c4b3a6857ede4eedc2fae2676ef02709aa4e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kidney Neoplasms - metabolism</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Proliferating Cell Nuclear Antigen - metabolism</topic><topic>Proto-Oncogene Proteins c-bcl-2 - metabolism</topic><topic>Survival Rate</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Tumors of the urinary system</topic><topic>Ureteral Neoplasms - metabolism</topic><topic>Ureteral Neoplasms - pathology</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NAKANISHI, K</creatorcontrib><creatorcontrib>TOMINAGA, S</creatorcontrib><creatorcontrib>KAWAI, T</creatorcontrib><creatorcontrib>TORIKATA, C</creatorcontrib><creatorcontrib>AURUES, T</creatorcontrib><creatorcontrib>IKEDA, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Virchows Archiv : an international journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NAKANISHI, K</au><au>TOMINAGA, S</au><au>KAWAI, T</au><au>TORIKATA, C</au><au>AURUES, T</au><au>IKEDA, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract</atitle><jtitle>Virchows Archiv : an international journal of pathology</jtitle><addtitle>Virchows Arch</addtitle><date>1998-05-01</date><risdate>1998</risdate><volume>432</volume><issue>5</issue><spage>445</spage><epage>450</epage><pages>445-450</pages><issn>0945-6317</issn><eissn>1432-2307</eissn><abstract>We investigated the immunoreactivity for bcl-2 oncoprotein in 154 cases of transitional cell carcinoma of the upper urinary tract (TCC-UUT) and its relation with the immunoreactivity for p53 oncoprotein and proliferating cell nuclear antigen (PCNA) immunoreactivity. Immunohistochemically, bcl-2 oncoprotein was recognized as positive in 29.2% of the samples. The immunoreactivity for bcl-2 oncoprotein was significantly (P &lt; 0.05) correlated only with stage, though there was a borderline correlation (P = 0.050) with PCNA immunoreactivity. Furthermore, in invasive TCC the immunoreactivity for bcl-2 oncoprotein was associated with PCNA immunoreactivity (P &lt; 0.041). The 5-year disease-free and overall survival rates were 55.7% and 71.5%, respectively. A univariate analysis of survival revealed that stage, grade, pattern of growth, immunoreactivity for p53 oncoprotein, and PCNA immunoreactivity each had a significant effect on disease-free and overall survival rates, whereas the immunoreactivity for bcl-2 oncoprotein had no significant effect on either rate. In the final models of the multivariate analysis, stage was found to be the only prognostic factor for disease-free survival and for overall survival. Detection of immunoreactivity for bcl-2 oncoprotein appears to be of no real value in deciding the prognosis of TCC-UUT.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>9645444</pmid><doi>10.1007/s004280050189</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0945-6317
ispartof Virchows Archiv : an international journal of pathology, 1998-05, Vol.432 (5), p.445-450
issn 0945-6317
1432-2307
language eng
recordid cdi_proquest_miscellaneous_79961187
source Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List
subjects Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinoma, Transitional Cell - metabolism
Carcinoma, Transitional Cell - pathology
Disease-Free Survival
Female
Humans
Immunohistochemistry
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Proliferating Cell Nuclear Antigen - metabolism
Proto-Oncogene Proteins c-bcl-2 - metabolism
Survival Rate
Tumor Suppressor Protein p53 - metabolism
Tumors of the urinary system
Ureteral Neoplasms - metabolism
Ureteral Neoplasms - pathology
Urinary tract. Prostate gland
title Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T00%3A25%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20bcl-2%20oncoprotein%20in%20transitional%20cell%20carcinoma%20of%20the%20upper%20urinary%20tract&rft.jtitle=Virchows%20Archiv%20:%20an%20international%20journal%20of%20pathology&rft.au=NAKANISHI,%20K&rft.date=1998-05-01&rft.volume=432&rft.issue=5&rft.spage=445&rft.epage=450&rft.pages=445-450&rft.issn=0945-6317&rft.eissn=1432-2307&rft_id=info:doi/10.1007/s004280050189&rft_dat=%3Cproquest_cross%3E79961187%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c383t-d44e2e8a9cb8b07a2d7144b0b79c4b3a6857ede4eedc2fae2676ef02709aa4e83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79961187&rft_id=info:pmid/9645444&rfr_iscdi=true